SB1518 for Patients With Myelodysplastic Syndrome (MDS)

Summary

The goal of this clinical research study is to learn if SB1518 can help to control myelodysplastic syndrome. The safety of the drug will also be studied. SB1518 is designed to block JAK2 and FLT3. SB1518 may have anti-tumor activity in certain leukemias, myelofibrosis, and lymphoma.

Timeline

Start

2011-12

Primary completion

2013-06

Completion

2013-06

Drugs

Indications